Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
Cherry AM, Slovak ML, Campbell LJ, Chun K, Eclache V, Haase D, Haferlach C, Hildebrandt B, Iqbal AM, Jhanwar SC, Ohyashiki K, Sole F, Vandenberghe P, VanDyke DL, Zhang Y, Dewald GW. Cherry AM, et al. Among authors: eclache v. Leuk Res. 2012 Jul;36(7):832-40. doi: 10.1016/j.leukres.2012.03.013. Epub 2012 Apr 25. Leuk Res. 2012. PMID: 22537394
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T, de Botton S, Taksin AL, Park S, Beyne-Rauzy O, Coiteux V, Sapena R, Lazareth A, Leroux G, Guenda K, Cassinat B, Fontenay M, Vey N, Guerci A, Dreyfus F, Bordessoule D, Stamatoullas A, Castaigne S, Terré C, Eclache V, Fenaux P, Adès L. Braun T, et al. Among authors: eclache v. Leuk Res. 2011 Jul;35(7):863-7. doi: 10.1016/j.leukres.2011.02.008. Epub 2011 Mar 10. Leuk Res. 2011. PMID: 21396711
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L. Sébert M, et al. Among authors: eclache v. Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27. Leuk Res. 2017. PMID: 29112938
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).
Nguyen-Khac F, Bidet A, Daudignon A, Lafage-Pochitaloff M, Ameye G, Bilhou-Nabéra C, Chapiro E, Collonge-Rame MA, Cuccuini W, Douet-Guilbert N, Eclache V, Luquet I, Michaux L, Nadal N, Penther D, Quilichini B, Terre C, Lefebvre C, Troadec MB, Véronèse L. Nguyen-Khac F, et al. Among authors: eclache v. Leukemia. 2022 Jun;36(6):1451-1466. doi: 10.1038/s41375-022-01561-w. Epub 2022 Apr 16. Leukemia. 2022. PMID: 35430613 Review.
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C. Kelaidi C, et al. Among authors: eclache v. Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29. Leuk Res. 2018. PMID: 30025278
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: eclache v. Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. Leukemia. 2011. PMID: 21468040 No abstract available.
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L. Le Bras F, et al. Among authors: eclache v. Leuk Res. 2011 Nov;35(11):1444-8. doi: 10.1016/j.leukres.2011.05.034. Epub 2011 Jun 28. Leuk Res. 2011. PMID: 21715006
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, Mozziconacci MJ, Maarek O, Mossafa H, Auger N, Dastugue N, Talmant P, Van den Akker J, Leonard C, N'Guyen Khac F, Mugneret F, Viguié F, Lafage-Pochitaloff M, Bastie JN, Roux GL, Nicolini F, Maloisel F, Vey N, Laurent G, Recher C, Vigier M, Yacouben Y, Giraudier S, Vernant JP, Salles B, Roussi J, Castaigne S, Leymarie V, Flandrin G, Lessard M; France Intergroupe pour la Leucemie Myeloide Chronique. Terre C, et al. Among authors: eclache v. Leukemia. 2004 Aug;18(8):1340-6. doi: 10.1038/sj.leu.2403399. Leukemia. 2004. PMID: 15190256
Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course.
Put N, Van Roosbroeck K, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L; BCGHo and the GFCH. Put N, et al. Among authors: eclache v. Ann Hematol. 2012 Jun;91(6):863-73. doi: 10.1007/s00277-011-1393-y. Epub 2011 Dec 30. Ann Hematol. 2012. PMID: 22205151
91 results